Cargando…

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response

BACKGROUND: Soft tissue sarcomas (STS) are heterogeneous and pro-metastatic tumors. Identification of accurate prognostic factors and novel therapeutic targets are crucial. CSPG4 is a cell surface proteoglycan with oncogenic functions. It recently emerged as a potential target for immunotherapy, inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boudin, Laurys, de Nonneville, A, Finetti, Pascal, Mescam, Léna, Le Cesne, A, Italiano, Antoine, Blay, Jean-Yves, Birnbaum, Daniel, Mamessier, Emilie, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552405/ https://www.ncbi.nlm.nih.gov/pubmed/36221119 http://dx.doi.org/10.1186/s12967-022-03679-y

Ejemplares similares

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Primary Synovial Sarcoma of the Thyroid Gland: Case Report and Review of the Literature
por: Boudin, Laurys, et al.
Publicado: (2014)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage
por: Hsu, Shu-Hsuan Claire, et al.
Publicado: (2018)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_smqn0etrpop7v0er0h4drhvs6c